Mirum Pharmaceuticals: Rare-Disease Platform, Not a One-Drug Story

Hook / Thesis

Mirum Pharmaceuticals has stopped trading like a single-product biotech and started pricing in platform potential. The company’s flagship asset Livmarli is producing the revenue foundation and management’s deal-making - notably the $620 million Bluejay Therapeutics acquisition - is an explicit push to build a multi-franchise rare liver-disease company. That transition creates an asymmetric trade: near-term earnings volatility and integration costs are likely, but the stock already reflects much of the commercial progress and leaves room for upside if pipeline candidates convert.

We like Mirum as a long trade around the current price because commercial momentum and bullish technicals give a clear entry point. At the same time, structural risks - a high short-interest backdrop, slowing 2026 growth guidance, and a stretched book value multiple - argue for a tight, disciplined stop-loss and a mid-to-long-term holding window.

Business overview and why the market should care

Mirum focuses on novel therapies for debilitating liver diseases. Its commercial product Livmarli (maralixibat) has driven recent revenue growth and helped the company reach near-term profitability in Q3 2025. Management has supplemented organic growth with the $620 million purchase of Bluejay Therapeutics to broaden indications and pipeline depth. For investors, the story is now about execution on two fronts: building consistent commercial growth from Livmarli and delivering proof points from mid-stage assets such as volixibat and MRM-3379 that expand the addressable market.

Key fundamentals you need to know

• Current market snapshot: current price $104.45, previous close $106.17, market cap ~$6.37 billion.
• Trading range and liquidity: 52-week high $112 (05/07/2026) and 52-week low $42.89 (05/23/2025); average daily volume ~1.11 million shares over recent periods, float ~50.6 million shares.
• Profitability and growth: Mirum reached profitability in Q3 2025 and reported revenue growth of 56.8% year-over-year through the first nine months. Management guided to slower sales growth for 2026 - 23.1% versus 54.4% in 2025 - partly reflecting acquisition-related dynamics and conservative modeling around new indications (01/31/2026).
• Balance and valuation cues: shares outstanding ~60.98 million and a P/B of 26.675 with a negative PE (-7.8) reflecting accounting nuances and the earnings profile post-acquisition.

Why this matters now

Two points make Mirum actionable today. First, the company has real commercial traction: reaching profitability in a biotech usually priced for operating losses is notable and reduces binary downside. Second, the technical picture is constructive: the 10-day SMA ($103.04) sits below price, the 9-day EMA (~$103.54) is supportive, MACD indicates bullish momentum and RSI in the high-50s suggests there is room to run without being overbought. Together, these fundamentals and technicals provide a defined entry/stop framework for a disciplined trade.

Valuation framing

Market cap of ~$6.37 billion reflects expectations for a multi-product growth profile, not purely Livmarli. That premium is visible in the high P/B of 26.7 and negative PE. For context, the stock doubled in price over the last 12 months and has recovered strongly from its 52-week low of $42.89. The implied valuation assumes sustained commercial execution plus successful launches or label expansions from pipeline assets. If Mirum converts even one mid-stage program into commercial reality or materially expands Livmarli indications, the current market cap would look reasonable; if it fails to integrate Bluejay or growth stalls at the guided 23% for 2026, downside is likely.

Trade plan (actionable)

• Direction: Long
• Entry price: 104.45
• Stop loss: 95.00
• Target price: 135.00
• Time horizon: long term (180 trading days) - this trade anticipates steady commercial execution and at least one meaningful clinical or regulatory catalyst within the next 4-9 months that can re-rate the shares.

Why these levels? Entry at $104.45 captures the current price where technical support (10-day SMA and short-term EMAs) has been defending intraday pullbacks. A stop at $95 limits downside from headline-driven volatility and sits below short-term support areas while leaving room for normal biotech noise. The $135 target requires multiple expansion toward a valuation that more fully credits the pipeline and successful integration of Bluejay - it is achievable if management demonstrates sustained revenue growth above guidance and pipeline readouts are positive.

Catalysts to watch (2-5)

• Commercial cadence: quarterly revenue prints and updated 2026 guidance showing acceleration above the current 23.1% growth assumption.
• Pipeline readouts for volixibat and MRM-3379 - positive efficacy signals would materially expand the market opportunity beyond Livmarli.
• Progress on Bluejay integration and cost synergies - clarity on how the $620M acquisition will add near-term revenue or drive long-term margin improvement.
• Regulatory milestones and label expansions that increase Livmarli’s eligible patient base.

Risks and counterarguments

Every trade has a flip side. Below are principal risks we are explicitly managing for this long idea, followed by one clear counterargument to the bullish case.

• Integration risk: The $620 million Bluejay acquisition increases scale but also brings one-time costs and execution risk; if integration overruns persist, EPS could be pressured and the valuation may compress.
• Slowing sales guidance: Management has tempered 2026 growth to 23.1% from the pace seen in 2025; if growth remains subdued or re-accelerates slower than feared, multiple compression is likely.
• High valuation metrics: A P/B of 26.7 and a negative PE mean the stock is priced for execution; any major miss in revenue or clinical development could trigger a steep correction back toward prior lows.
• Short-interest and liquidity-driven volatility: Short interest around 8.4 million shares (settlement 04/30/2026) and days-to-cover above 14 indicate the potential for fast moves in either direction and amplify headline sensitivity.
• Clinical binary risk: Pipeline assets are not guaranteed to succeed; negative readouts could erase implied optionality quickly.

Counterargument: The bear case is straightforward - you can make a credible argument that Mirum is a high-priced commercial biotech with one material revenue generator and several developmental programs. If Livmarli growth disappoints and acquisition costs continue to depress margins, the market could re-rate the company toward a single-digit multiple on revenue, sending shares far below current levels. That is why a stop at $95 is critical for risk control.

What would change our view

We would become more bullish if Mirum reports two consecutive quarters of revenue growth that exceed the 23.1% guidance and demonstrates tangible synergies or new indications from the Bluejay assets. Conversely, we would reduce conviction if management cut 2026 guidance again, if pipeline readouts show negative efficacy, or if integration costs materially exceed current expectations and push the company back into sustained losses.

Conclusion

Mirum sits at an inflection: commercial momentum and a growing pipeline make the company more than a one-drug story, but that upside is not free. The trade outlined - long at $104.45 with a $95 stop and a $135 target over a 180-trading-day horizon - balances upside optionality with disciplined risk control. This is a trade for investors willing to live with biotech volatility in exchange for the chance that Mirum’s platform expands its addressable market and re-rates the business to a higher multiple.

Trade idea summary: Long MIRM at $104.45, stop $95, target $135, horizon long term (180 trading days). Protect capital but be patient - this is about execution, not a binary catalyst.